Loading clinical trials...
Loading clinical trials...
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Shanghai Gynecologic Oncology Group
Collaborators
NCT06710548 · Ovarian Cancer, Advanced Ovarian Carcinoma, and more
NCT07303218 · EGFR, Non Small Cell Lung Cancer, and more
NCT06055166 · PARP Inhibitor for Esophageal Squamous Cell Carcinoma
NCT04566952 · Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions